GV returned to reinvest in small molecule drug developer Ventus Therapeutics having backed its $60m series A round almost a year ago.
US-based small molecule drug developer Ventus Therapeutics completed a $100m series B round yesterday featuring GV, a corporate venture capital subsidiary of internet and technology group Alphabet. Investment manager RA Capital Management led the round, which included Alexandria Venture Investments, the VC arm of real estate investment trust Alexandria Real Estate Equities, as well as…
This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.